It is understood that drugs targeting the PD-1/PD-L1 pathway exert their influence by re-invigorating exhausted T cells within the tumor microenvironment [60], but recent studies indicate that there may be many more interactions at play here than first initially realized. The gene discussed is PDCD1; the disease is neoplasm.